STTR Phase II: High Throughput Aligned Nanofiber Multiwell Plates for Glioblastoma Research

这个小企业技术转让第二阶段项目旨在解决高通量，成本效益的工具来模拟脑癌细胞转移的未满足的需求。拟议的第二阶段工作将实现广泛采用所需的三个关键目标：1）在多孔板生产过程中消除粘合剂的使用，2）利用Sterigenics伽马辐照设施实施FDA批准的灭菌程序，以及3）额外的生物数据提供了我们的产品与已经上市的产品的直接比较，同时也创造了市场“拉力”该技术在脑癌临床治疗中的药物应用。高通量细胞培养迁移试验的供应将使研究人员能够以前所未有的方式了解和治疗癌症转移。预计该项目的结果将是更快，更有效的药物开发，以治疗脑癌和其他转移性癌症。一旦生产条件完全建立，预计该技术将扩展到其他类型的癌症和组织工程领域。该项目更广泛的影响/商业潜力在于，它将提供改进的、更准确的胶质瘤迁移模型，具有更好的预测能力和更高的翻译潜力。目前用于恶性脑肿瘤的外科手术不能去除与原发性肿瘤相关的所有细胞，并且这些癌细胞迁移到周围组织中，在那里它们逃避检测和当前的化疗，导致继发性肿瘤形成和接近100%的患者死亡率。多孔板体外迁移试验将使药物研究能够确定调节胶质瘤细胞迁移的关键因素，可能有助于设计针对这些毁灭性肿瘤的广泛有效疗法和药物。如果这种最初形式的高通量运动测定是成功的，它将提供一个创新的工具，适用于来自胶质瘤治疗和癌症之外的各种背景的研究人员。此外，到2012年，全球细胞/组织培养用品市场预计将达到49.7亿美元，因此存在强大的商业潜力;该市场包括拟议的消耗性研究工具。

This Small Business Technology Transfer Phase II project seeks to address the unmet need for high-throughput, cost effective tools to model the metastasis of brain cancer cells. The proposed Phase II work will achieve three key objectives necessary for broad adoption: 1) eliminating the use of adhesive during multiwell plate production, 2) implement FDA-approved sterilization procedures utilizing the Sterigenics gamma radiation facility, and 3) additional biological data providing both a head-to-head comparison of our products to those already on the market while also creating a market "pull" for the pharmaceutical application of this technology in clinical treatments of brain cancer. A supply of high-throughput cell culture migration assays will allow researchers to understand and treat cancer metastasis in ways never before possible. It is anticipated that a result of this project will be faster and more effective drug developments to treat brain cancer and other metastasizing cancers. Extension of this technology to other types of cancer and areas of tissue engineering is anticipated once production conditions are fully established.The broader impact/commercial potential of this project is that it will provide improved, more accurate models of glioma migration having better predictive power and higher translational potential. Current surgical procedures for malignant brain tumors cannot remove all of the cells associated with the primary tumor and these cancer cells migrate into the surrounding tissue where they evade both detection and current chemotherapies, leading to secondary tumor formation and nearly 100% patient mortality. A multi-well plate in vitro migration assays will enable pharmaceutical research identifying key factors regulating glioma cell migration, potentially helping devise a broad range of effective therapies and drugs against these devastating tumors. If this initial form of high-throughput motility assay is successful, it will provide an innovative tool appropriate for researchers from a large variety of backgrounds beyond both glioma treatments and cancer. Additionally, strong commercial potential exists as the cell/tissue culture supplies market is expected to reach $4.97 billion globally by 2012; this market includes the proposed consumable research tool.